India’s nutraceutical industry is entering a decisive new phase, with the market projected to approach USD 24 billion by 2032 and the conversation shifting from hype to hard science, safety, and systems. The sector is moving away from an “alternative to allopathy” tag and towards becoming a serious, evidence-led pillar of preventive and integrative healthcare in India.
Riding The Preventive Health Wave
India’s rising burden of lifestyle disorders, an ageing population, and urban stress have reshaped how consumers think about health. Instead of waiting for illness, more people are seeking preventive solutions for metabolic health, gut function, mental wellness, healthy ageing, and women’s health. Within this shift, nutraceuticals and Ayurveda-based products are gaining traction as everyday health supports rather than occasional supplements.
According to Dr Arunkanth Krishnakumar, Co-founder and CEO of Zeus Hygia Lifesciences, India’s nutraceutical growth is fundamentally being driven by this preventive mindset. Consumers are “increasingly seeking natural sources, science-backed, clean-label, and condition-specific solutions” and are actively looking for clinically validated and bioavailable ingredients rather than generic formulations. This marks an important evolution from a volume-led market to one where efficacy, differentiation, and science are core competitive levers.
On the Ayurveda side, a parallel transformation is under way. Kiran Chandrasekeran, Head of Products at Apollo AyurVAID Hospitals, points out that Ayurveda’s growth is now being reshaped by credibility, safety, and clinical integration. The shift, he says, is from casual over-the-counter use to structured, doctor-driven, root-cause care. Consumers are moving beyond short-term symptom relief and demanding sustained, holistic solutions for inflammation, gut balance, cognitive wellness, and long-term metabolic resilience. He also notes that preventive healthcare spending in India is growing faster than curative segments, underscoring a durable behavioural shift.
Capital Backs Science-Led, Systems-Driven Models
The investment narrative is evolving in tandem with this demand transformation. For nutraceuticals, Dr Krishnakumar observes strong interest from pharmaceutical companies, private equity investors, and global nutrition players. Capital is flowing not only into consumer brands, but deeper into the ecosystem with branded functional ingredients, contract manufacturing, digital health platforms that integrate nutrition, and clinical research capabilities. It signals rising confidence in India’s ability to scale, innovate, and serve both domestic and export markets.
In Ayurveda, Chandrasekeran notes that investors are moving beyond pure-play D2C brands towards organisations with robust manufacturing systems, quality testing protocols, regulatory discipline, and export readiness. Ayurveda and herbal segments, he points out, are growing at an estimated 10 to 15 percent CAGR, outpacing several traditional FMCG categories. The future, in his view, belongs to companies that can integrate authentic traditional systems with modern science, data, and clinical evidence.
Apollo AyurVAID’s own brands, AyurVAID and AvestaAyurVAID, are positioned as examples of this next-generation model. AyurVAID has been positioned as India’s “1st and only Tested-Safe Ayurveda Medicines,” institutionalising batch-wise heavy metal testing through NABL-accredited laboratories, GMP-driven manufacturing, and end-to-end traceability. AvestaAyurVAID builds on this foundation by combining classical formulations with modern bioactive research, safety validation, and cell-line studies, particularly in condition-focused medical nutrition and bioactive hydration.
Safety, Compliance, And Trust As The New Moat
As the sector scales, both experts emphasise that long-term credibility rests on safety, regulation, and certification rather than marketing. Dr Krishnakumar stresses that robust regulatory frameworks, strict adherence to FSSAI guidelines, international certifications, and clinical substantiation are now essential for building consumer trust. Companies that prioritise transparency, traceability, and evidence-based claims, he argues, will lead the next phase of sustainable growth and clearly differentiate themselves from low-quality operators.
Chandrasekeran echoes this but takes it a step further for Ayurveda. In his view, long-term trust in Ayurveda is built “not on claims but on compliance,” clarity about who a product is for and who it is not for, and clear accountability. India’s AYUSH standards, the Drugs and Cosmetics Act (ASU), Schedule T GMP, and FSSAI have strengthened the regulatory backbone, but he believes the real differentiator will be brands that go beyond minimum compliance. Proactive safety validation—especially batch-wise heavy metal testing aligned with pharmacopoeial standards, independent NABL lab reports, and transparent Certificates of Analysis—will be central to building lasting trust with both patients and physicians.
Apollo AyurVAID’s Tested-Safe framework is presented as proof that classical formulations can be standardised, traceable, clinically integrated, and globally compliant. The company’s bioactive hydration drinks, built on science-validated ingredients and advanced testing systems, are designed to deliver measurable, condition-focused outcomes, reinforcing the idea that Ayurveda can operate with the same rigour as modern therapeutics when systems are designed correctly.
From Raw Material Base To Innovation Hub
Looking ahead, both experts see India at a strategic crossroads in the global nutraceutical value chain. Historically viewed largely as a low-cost raw material base, India now has the opportunity to reposition itself as a global innovation hub. Dr Krishnakumar believes this shift will be enabled by the country’s biodiversity, scientific talent, cost-efficient manufacturing, and a growing clinical research ecosystem. For him, the future lies in branded, clinically supported ingredients that meet global regulatory and quality benchmarks rather than in commodity ingredients alone.
Chandrasekeran frames India’s opportunity in Ayurveda not as one of scale alone, but of credibility and leadership. While India has unparalleled medicinal biodiversity and codified classical knowledge, he stresses that global competitiveness will depend on regulatory harmonisation with agencies such as the USFDA and European regulators, adherence to pharmacopeial standards, validated contaminant limits, transparent labelling, robust stability data, and clinically documented outcomes. The world, he argues, does not need “low-cost Ayurveda”; it needs standardised, tested, safe, clinically positioned Ayurveda that can withstand global scrutiny.
As India’s nutraceutical and Ayurveda ecosystems mature, the sector’s centre of gravity is shifting from product proliferation and marketing narratives to systems, science, and safety. The companies most likely to lead this market will be those that build their advantage not just on formulations or price, but on trust—earned through compliance, clinical substantiation, and transparent, patient-centred systems.
